# Omicron BA.4/5-Delta Strain Recombinant Novel Coronavirus Protein Vaccine (CHO Cells)

> **NCT05850507** · NA · COMPLETED · sponsor: **Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.** · enrollment: 450 (actual)

## Conditions studied

- Coronavirus

## Interventions

- **BIOLOGICAL:** Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells)
- **BIOLOGICAL:** Recombinant novel coronavirus protein vaccine (CHO cells)

## Key facts

- **NCT ID:** NCT05850507
- **Lead sponsor:** Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-17
- **Primary completion:** 2023-10-17
- **Final completion:** 2024-03-20
- **Target enrollment:** 450 (ACTUAL)
- **Last updated:** 2024-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05850507

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05850507, "Omicron BA.4/5-Delta Strain Recombinant Novel Coronavirus Protein Vaccine (CHO Cells)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05850507. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*